Binaytara Foundation Hosted a CME conference, CheckPoint Inhibitors in Lung Cancer, in Everett, Washington

The Binaytara Foundation hosted a CME conference, CheckPoint Inhibitors in Lung Cancer, on March 26, 2022, at the Delta Hotels in Everett, Washington. This half-day conference was the first in a series of mini oncology conferences the Binaytara Foundation plans to host across several parts of the Pacific Northwest. Designed to provide an active learning opportunity and direct participation of community oncologists in discussions, the Binaytara Foundation’s mini-conferences offer oncologists and oncology nurses an intimate atmosphere for learning, networking, and collaboration among community oncologists and academic physicians. These accredited oncology continuing education activities (CME) are highly rated by participants and focus on enabling oncology practitioners to interpret and implement practice-changing research findings into their day-to-day clinical practices. 

The live continuing education activity, Checkpoint Inhibitors in Lung Cancer conference, featured lectures by two lung cancer experts from Seattle, Cristina Merkhofer, MD, MHS & Rafael, Santana-Davila, MD, both from the Fred Hutchinson Cancer Center, followed by tumor board style case presentations and discussions with local oncologists, Mehrdad Jafari, MD, Ph.D. from Skagit Regional Health, Arthur Molina III MD from Skagit Regional Health, Joseph Rosales, MD from Virginia Mason Medical Center, Guobin Song, MD, Ph.D. from Virginia Mason Medical Center. 

Young volunteer, Jaya, helping attendees at the registration desk during the lung cancer conference on March 26, 2022

The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education (CME) for physicians. The Binaytara Foundation is also approved by the California Board of Registered Nursing to provide continuing education to nurses. In 2021 alone, the Binaytara Foundation provided continuing education to nearly 1000 healthcare providers from different parts of the country and internationally through our in-person, virtual, and self-paced continuing medical education activities. 

Expanding beyond the Lung Cancer mini-conference

The Binaytara Foundation plans to organize a series of similar mini oncology conferences in other parts of Washington as well as other Pacific Northwest states – Idaho, Montana, Wyoming, Alaska, and Oregon. These mini oncology conferences will provide continuing education credits to oncologists and nurses, and follow an educational format similar to this last lung cancer conference held in Everett, WA on March 26th. The mini oncology conferences will focus on specific disease updates such as lung cancer, breast cancer, Hematologic Malignancies, gastro-intestinal cancers, renal cancers, and other general cancers.

The next in the series, Montana Hematology Conference, will be held in Whitefish, Montana on May 13th, 2022. This hematology conference will feature hematologists from the University of Utah, Huntsman Cancer Institute and local oncologists from Montana as faculty. We expect approximately 18 healthcare providers from Montana and Utah to participate in this accredited oncology continuing education activity. 

Missed the live conference? We have many self-paced CME activities on Lung Cancer and more!

In addition to these mini-conferences & large-scale in-person live conferences, the Binaytara Foundation Education Academy offers several self-paced accredited continuing education (CME) activities for oncologists and oncology nurses interested in earning free continuing education credits at their own convenience. These activities include journal-based CME as well as recorded webcasts. All self-paced CME activities available on the Binaytara Foundation Eduction Academy are free for healthcare providers not employed by the biopharma industry. Many of these self-paced activities also offer Maintenance of Certificate (MOC) points to eligible physicians. Register on our education academy and start learning and earning free CME credits.

Staff Writer - The Cancer News

Recent Posts

ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC)

By: Tiantian Zhang1, Yiqun Han2, Lei Deng3 1. Department of Internal Medicine, University of Central…

7 months ago

ASCO24 LAURA Trial Summary

By: Zhiting Tang1, Lei Deng21. Unity Hospital, Rochester Regional Health, Rochester, NY2. University of Washington/Fred…

7 months ago

FDA Approves Tovorafenib for Pediatric Low-Grade Glioma With BRAF Mutation

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug…

7 months ago

FDA Approves Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 29, 2024, the U.S. Food and Drug…

7 months ago

FDA Approves Lutetium Lu 177 Dotatate for SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug…

7 months ago

FDA Approves Alectinib for Adjuvant Treatment in Non-Small Cell Lung Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 18, 2024, the U.S. Food and Drug…

7 months ago